Mankind Pharma is a renowned Indian pharmaceutical and healthcare products company, headquartered in Delhi. Since its inception in 1991, the company has rapidly grown to become a prominent player in the pharmaceutical industry, actively commencing its operations in 1995.
The company’s product portfolio covers a wide array of therapeutic areas. Mankind Pharma is committed to delivering high-quality and affordable healthcare solutions, aiming to improve the lives of millions worldwide.
This article aims to explore the share price target of Mankind Pharma from 2023 to 2030, as well as analyze the viability of Mankind Pharma as a promising stock to consider for investment.
LATEST NEWS ABOUT MANKIND PHARMA
- Among the list of overbought stocks showing bearish Relative Strength Index (RSI), Shriram Finance and Mankind Pharma are two notable companies.
- Mankind Pharma experiences a significant surge as it enters the Nifty Indices, replacing HDFC.
HOW TO BUY MANKIND PHARMA SHARES ?
You can buy Mankind Pharma shares from the following trading platforms:
- Zerodha
- Upstox
- Groww
- AngleOne
- ICICIDirect
SHARE PRICE PREDICTION OF MANKIND PHARMA:2023 TO 2030
SHARE PRICE TARGET 2023 OF MANKIND PHARMA
| When | Maximum Price | Minimum Price |
| July 2023 | ₹1,982.40 | ₹1,802.18 |
| August 2023 | ₹2,022.05 | ₹1,838.23 |
| September 2023 | ₹2,068.56 | ₹1,880.50 |
| October 2023 | ₹2,008.31 | ₹1,825.73 |
| November 2023 | ₹2,048.47 | ₹1,862.25 |
| December 2023 | ₹2,109.93 | ₹1,918.11 |
In 2023, Mankind Pharma’s share price demonstrated impressive growth, with the stock reaching notable milestones throughout the year. In July 2023, the share price fluctuated between ₹1,802.18 and ₹1,982.40. The upward trend continued into August, with the stock witnessing a price range of ₹1,838.23 to ₹2,022.05. As the months progressed, Mankind Pharma’s growth remained consistent, achieving a price range of ₹1,880.50 to ₹2,068.56 in September, and ₹1,825.73 to ₹2,008.31 in October.
During November 2023, the share price further advanced, ranging between ₹1,862.25 and ₹2,048.47, indicating a steady upward trajectory. The year concluded with an impressive surge in December, where the stock price reached its highest range of ₹1,918.11 to ₹2,109.93.
Throughout the year, Mankind Pharma’s share price exhibited substantial growth, reflecting the company’s strong performance and investor confidence. The overall growth percentage in 2023 showcases the company’s remarkable progress and potential for future success in the pharmaceutical industry. Investors and stakeholders eagerly anticipate the continued growth and performance of Mankind Pharma in the years ahead.
SHARE PRICE TARGET 2024 OF MANKIND PHARMA
| When | Maximum Price | Minimum Price |
| January 2024 | ₹2,220.97 | ₹1,931.28 |
| February 2024 | ₹2,414.10 | ₹2,099.22 |
| March 2024 | ₹2,438.49 | ₹2,120.42 |
| April 2024 | ₹2,216.81 | ₹1,927.66 |
| May 2024 | ₹1,847.34 | ₹1,606.38 |
| June 2024 | ₹2,216.81 | ₹1,927.66 |
| July 2024 | ₹1,884.29 | ₹1,638.51 |
| August 2024 | ₹2,072.71 | ₹1,802.36 |
| September 2024 | ₹2,176.35 | ₹1,892.48 |
| October 2024 | ₹2,560.41 | ₹2,226.45 |
| November 2024 | ₹2,688.43 | ₹2,337.77 |
| December 2024 | ₹2,742.20 | ₹2,384.52 |
In 2024, Mankind Pharma’s share price continued its upward trajectory, showcasing remarkable growth and resilience in the pharmaceutical market. The year began with a strong start in January, with the share price ranging from ₹1,931.28 to ₹2,220.97. This positive momentum persisted into February and March, with the stock reaching a range of ₹2,099.22 to ₹2,414.10 and ₹2,120.42 to ₹2,438.49, respectively.
While the share price experienced a slight dip in April, ranging from ₹1,927.66 to ₹2,216.81, Mankind Pharma quickly rebounded and regained its upward momentum in May, reaching a range of ₹1,606.38 to ₹1,847.34.
As the year progressed, the stock witnessed fluctuations, but the overall growth trend remained impressive. In June, the share price once again reached a range of ₹1,927.66 to ₹2,216.81, demonstrating the company’s resilience and stability.
Throughout the year, Mankind Pharma’s share price experienced periods of growth, reaching significant milestones. In November and December, the stock price soared to ₹2,337.77 to ₹2,688.43 and ₹2,384.52 to ₹2,742.20, respectively, showcasing the company’s exceptional performance and investor confidence.
The growth percentage of Mankind Pharma in 2024 was substantial, reflecting the company’s strong market presence, strategic initiatives, and successful product portfolio. Investors and stakeholders were pleased with the consistent growth trajectory of the company’s share price, further solidifying Mankind Pharma’s position as a leading player in the pharmaceutical industry. As the company continues to expand its reach and innovations, there is a positive outlook for Mankind Pharma’s future growth and potential for continued success in the market.
SHARE PRICE TARGET 2025 OF MANKIND PHARMA
| When | Maximum Price | Minimum Price |
| January 2025 | ₹2,797.05 | ₹2,151.57 |
| February 2025 | ₹2,944.26 | ₹2,264.81 |
| March 2025 | ₹3,091.47 | ₹2,378.06 |
| April 2025 | ₹2,760.24 | ₹2,123.26 |
| May 2025 | ₹2,509.31 | ₹1,930.24 |
| June 2025 | ₹2,760.24 | ₹2,123.26 |
| July 2025 | ₹2,628.80 | ₹2,022.16 |
| August 2025 | ₹2,738.34 | ₹2,106.41 |
| September 2025 | ₹2,875.25 | ₹2,211.73 |
| October 2025 | ₹3,047.77 | ₹2,344.44 |
| November 2025 | ₹3,261.11 | ₹2,508.55 |
| December 2025 | ₹3,326.33 | ₹2,558.72 |
In 2025, Mankind Pharma’s share price experienced a remarkable surge, solidifying its position as a leading player in the pharmaceutical industry. The year commenced with a strong performance in January, as the share price reached an impressive range of ₹2,151.57 to ₹2,797.05. This positive momentum continued into February and March, with the stock hitting highs of ₹2,264.81 to ₹2,944.26 and ₹2,378.06 to ₹3,091.47, respectively.
Despite some fluctuations, Mankind Pharma maintained its growth trajectory throughout the year. In April, the share price ranged from ₹2,123.26 to ₹2,760.24, while in May, it reached ₹1,930.24 to ₹2,509.31.
June saw a similar pattern to April, with the share price ranging from ₹2,123.26 to ₹2,760.24. However, the company picked up momentum in July, reaching ₹2,022.16 to ₹2,628.80.
As the year progressed, Mankind Pharma continued to impress investors and stakeholders. The share price witnessed steady growth in August, reaching ₹2,106.41 to ₹2,738.34. This upward trend continued into September, with the stock ranging from ₹2,211.73 to ₹2,875.25.
In October, the share price further surged, achieving a range of ₹2,344.44 to ₹3,047.77. November proved to be another exceptional month for Mankind Pharma, with the share price soaring to ₹2,508.55 to ₹3,261.11.
The year concluded on a high note in December, as the share price reached an impressive range of ₹2,558.72 to ₹3,326.33. This demonstrated the company’s strong performance and investor confidence.
MANKIND PHARMA SHARE PRICE PREDICTION 2026-2030
| Year | Maximum Price | Minimum Price |
| 2026 | ₹2,328.43 | ₹1,629.90 |
| 2027 | ₹1,979.17 | ₹1,385.42 |
| 2028 | ₹3,562.50 | ₹2,493.75 |
| 2029 | ₹7,317.93 | ₹5,122.55 |
| 2030 | ₹8,149.52 | ₹5,704.66 |
Between 2026 and 2030, Mankind Pharma’s share price demonstrated both periods of growth and fluctuations, showcasing the dynamic nature of the pharmaceutical industry. In 2026, the share price ranged from ₹1,629.90 to ₹2,328.43, reflecting a positive trajectory.
However, in 2027, there was a dip in the share price, with the range between ₹1,385.42 to ₹1,979.17. This period might have been influenced by various factors affecting the market and the company’s performance.
In 2028, Mankind Pharma experienced a substantial surge, as the share price reached a remarkable range of ₹2,493.75 to ₹3,562.50. This significant growth could have been attributed to successful product launches, strategic initiatives, or other market drivers.
The growth trend continued into 2029, as the share price reached an impressive range of ₹5,122.55 to ₹7,317.93. This remarkable jump in share price could have been driven by strong financial performance, expansion into new markets, or breakthrough developments.
In 2030, Mankind Pharma’s share price continued its upward trajectory, reaching a range of ₹5,704.66 to ₹8,149.52. This period likely saw continued success in the company’s endeavors, making it an attractive investment opportunity.
FINANCIAL CONDITION OF MANKIND PHARMA :LAST 5 YEARS
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
| Sales | 3,829 | 4,794 | 5,523 | 7,257 | 8,127 |
| Expenses | 3,124 | 3,550 | 4,151 | 5,457 | 6,430 |
| Operating Profit | 705 | 1,244 | 1,372 | 1,800 | 1,697 |
| OPM % | 18% | 26% | 25% | 25% | 21% |
| Other Income | 64 | 94 | 154 | 163 | 163 |
| Interest | 40 | 11 | 8 | 44 | 28 |
| Depreciation | 38 | 62 | 78 | 121 | 270 |
| Profit before tax | 691 | 1,265 | 1,440 | 1,798 | 1,563 |
| Tax % | 26% | 24% | 25% | 26% | 20% |
| Net Profit | 514 | 958 | 1,084 | 1,335 | 1,248 |
| EPS in Rs | 12.83 | 23.92 | 27.07 | 33.33 | 31.16 |
| Dividend Payout % | 0% | 32% | 0% | 0% | 0% |
The financial data for Mankind Pharma from March 2019 to March 2023 indicates a consistent growth trajectory with a few fluctuations in certain aspects. The Sales revenue steadily increased over the years, rising from ₹3,829 crores in March 2019 to ₹8,127 crores in March 2023. Similarly, the company’s Expenses also grew, reflecting the expansion of its operations and business activities.
Mankind Pharma’s Operating Profit (OP) witnessed steady growth, with the figures climbing from ₹705 crores in March 2019 to ₹1,697 crores in March 2023. The Operating Profit Margin (OPM %) experienced fluctuations, but it generally remained stable, ranging from 18% to 26%.
The Net Profit increased over the years, going from ₹514 crores in March 2019 to ₹1,248 crores in March 2023. However, there were fluctuations in the growth rate.
The Earnings Per Share (EPS) of Mankind Pharma showed steady growth, increasing from ₹12.83 in March 2019 to ₹31.16 in March 2023.
The Dividend Payout percentage remained at 0% during the entire period, indicating that the company did not distribute dividends to its shareholders during this time.
Overall, Mankind Pharma demonstrated consistent growth in its financial performance, with rising sales, operating profit, and net profit. While there were fluctuations in some aspects, the company maintained a strong position in the pharmaceutical industry and retained its focus on reinvesting profits for future growth and expansion rather than paying dividends to shareholders.
FAQS
COULD THE SHARE PRICE OF MANKIND PHARMA POTENTIALLY INCREASE IN 2023 ?
Yes, it is anticipated that Mankind Pharma share price will increase to ₹2,109 by the end of 2023.
WHAT HAS BEEN THE REVENUE GROWTH RATE OF MANKIND PHARMA OVER THE LAST FIVE YEARS?
The approximate average growth of Mankind Pharma over the last 5 years is around 28.17%.
WHAT IS THE PROJECTED SHARE PRICE TARGET OF MANKIND PHARMA FOR THE YEAR 2025?
Mankind pharma share price might reach around ₹3,326 by the end of 2025.
WHAT IS THE PROJECTED SHARE PRICE TARGET OF MANKIND PHARMA FOR THE YEAR 2030?
Mankind pharma share price might reach around ₹8,149 by the end of 2030.
WHAT FACTORS OR DATA SERVE AS THE BASIS FOR PROJECTING THE TARGET SHARE PRICE FOR MANKIND PHARMA ?
The projected target share price for Mankind Pharma is based on various factors, including the company’s financial performance, growth prospects, industry trends, and market sentiment.
Also Read:
- CG POWER AND INDUSTRIAL SOLUTIONS SHARE PRICE TARGET OF 2023,2024,2025 TO 2030
- ZEE ENTERTAINMENT ENTERPRISES SHARE PRICE TARGET OF 2023,2024,2025 TO 2030
- SUPREME INDUSTRIES SHARE PRICE TARGET OF 2023,2024,2025 TO 2030
- JUST DIAL SHARE PRICE TARGET OF 2023,2024,2025 TO 2030
CONCLUSION
The company’s sales revenue has steadily increased, demonstrating strong market demand for its pharmaceutical products. The operating profit margin remained stable, indicating effective cost management and operational efficiency.
Moreover, Mankind Pharma’s net profit has experienced substantial growth, which showcases the company’s ability to generate higher returns for its investors. The earnings per share (EPS) has also shown a positive trend, indicating that the company is generating greater profits for each outstanding share.
Overall, the data suggests that Mankind Pharma has been a promising investment option, given its consistent growth and financial performance over the last 5 years. However, as with any investment, it’s essential for investors to conduct thorough research and consider various factors before making any decisions. Factors such as the pharmaceutical industry’s regulatory environment, competition, and economic conditions should also be taken into account when assessing the potential growth and investment prospects of Mankind Pharma.
Leave a Reply